Dietary supplementation with conjugated linoleic acid increased its concentration in human peripheral blood mononuclear cells, but did not alter their function.
The purpose of this study was to examine if conjugated linoleic acid (CLA) supplementation of diets would alter fatty acid (FA) composition and function of peripheral blood mononuclear cells (PBMC). Seventeen women, 20-41 yr, participated in a 93-d study conducted at the Metabolic Research Unit. The same diet (19, 30, and 51% energy from protein, fat, and carbohydrate, respectively) was fed to all subjects throughout the study. Seven subjects (control group) supplemented their diet with six daily capsules (1 g each) of placebo oil (sunflower) for 93 d. For the other 10 subjects (CLA group), the supplement was changed to an equivalent amount of Tonalin capsules for the last 63 d of the study. Tonalin provided 3.9 g/d of a mixture of CLA isomers (trans-10,cis-12, 22.6%; cis-11,trans-13, 23.6%; cis-9,trans-11, 17.6%; trans-8,cis-10, 16.6%; other isomers 19.6%), and 2.1 g/d of other FA. PBMC isolated on study days 30 and 90 were used to assess intracellular cytokines by flow cytometry, secreted cytokines, and eicosanoid by enzyme-linked immonosorbent assay, and FA composition by gas-liquid chromatography. After supplementation, total CLA concentration increased from 0.012 to 0.97% (P < 0.0001) in PBMC lipids, but it did not significantly alter the concentration of other FA. CLA supplementation did not alter the in vitro secretion of prostaglandin E2, leukotriene B4, interleukin-1beta (IL-1beta), or tumor necrosis factor alpha (TNFalpha) by PBMC simulated with lipopolysaccharide, and the secretion of IL-2 by PBMC stimulated with phytohemagglutinin. Nor did it alter the percentage T cells producing IL-2, interferon gamma, and percentage of monocytes producing TNFalpha. The intracellular concentration of these cytokines was also not altered. None of the variables tested changed in the control group. Our results show that CLA supplementation increased its concentration in PBMC lipids, but did not alter their functions.
Kelley
D S
DS
U.S. Department of Agriculture, Western Human Nutrition Research Center, University of California, Department of Nutrition, Davis 95616, USA. dkelley@whnrc.usda.gov
Simon
V A
VA
Taylor
P C
PC
Rudolph
I L
IL
Benito
P
P
Nelson
G J
GJ
Mackey
B E
BE
Erickson
K L
KL
D000328:Adult; D004032:Diet; D019587:Dietary Supplements; D015232:Dinoprostone / Q000378:metabolism; D002149:Energy Intake; D005227:Fatty Acids / Q000097:blood; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D007375:Interleukin-1 / Q000378:metabolism; D007376:Interleukin-2 / Q000096:biosynthesis; D007963:Leukocytes, Mononuclear / Q000737:chemistry / Q000502:physiology*; D007975:Leukotriene B4 / Q000378:metabolism; D019787:Linoleic Acid / Q000008:administration & dosage* / Q000097:blood*; D008070:Lipopolysaccharides / Q000494:pharmacology; D010919:Placebos; D013601:T-Lymphocytes / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D005227:Fatty Acids; D007375:Interleukin-1; D007376:Interleukin-2; D008070:Lipopolysaccharides; D010919:Placebos; D014409:Tumor Necrosis Factor-alpha; D007975:Leukotriene B4; D007371:Interferon-gamma; D019787:Linoleic Acid; D015232:Dinoprostone